Thursday, March 19, 2009
A new survey released by IBM and Silico Research reveals that if life science companies fail to collaborate, they risk costly delays in the production of new medicines, medical devices, diagnostics, and support services. The survey also spotlights a paradox regarding alliances between larger and smaller life science firms.
During this week's GEN podcast, IBM's Salima Lin defines the paradox and offers suggestions on how biotech and pharmaceutical companies can work together more effectively. She also lists the key factors that drive companies to collaborate with one another and discusses what small companies look for in collaborations with larger firms and vice versa.
Lin talks about survey results indicating which large life science firms are considered good partners and why. She also takes a close look at those big pharma companies found to be lacking in the qualities that make for a promising partner.
Lin explores those aspects of a life science alliance that need to be measured to assess its productivity and describes four steps companies should follow to become more sought-after partners.
3/27/2009
Podcasts such as this one are very valuable and complimentary to articles and news stories. Good investment of my time. Thanks.
NOTICE: As such, the comments on this blog were, are, and will always be solely the opinions of the individuals leaving them. In no way does Genetic Engineering & Biotechnology News, GEN Publishing, Inc., or Mary Ann Liebert ,Inc. endorse, condone, agree with, sponsor, etc. these comments.
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
HOME
Hot Topics
All Topics
Archived
Post a Topic
RSS
LISTEN
COMMENT
Email
Print
Back
Share
Save